> Physiology > Organ or Tissue Function > Coagulation, Blood

Coagulation, Blood

Coagulation, Blood: The process of blood clot formation, involving complex interactions between blood vessels, blood platelets, and numerous coagulation factors.
This essential physiological mechanism helps stop bleeding and promotes healing.
Explore advanced AI-powered tools to streamline your Coagulation and Blood research protocols, and uncover the most efficient and effective published methods to advance your studies.

Most cited protocols related to «Coagulation, Blood»

Defining Disease Activity Change in Lupus

Change in therapy has been chosen as the reference standard for disease activity and used as the response (outcome) variable. This is based on the well-defined benchmark for active disease, which is the decision to treat and is in line with the previous study that derived the scoring for the Classic BILAG index [6 (link)].
A robust definition for change in therapy was used, similar to the definition used in our previous study [6 (link)]. Change in therapy was the change in treatment following the assessment. The medications of interest included immunosuppressives, anti-malarials, glucocorticoids, biological therapy, topical glucocorticoids, topical immunosuppressives, intravenous immunoglobulins, plasmapheresis, anti-coagulation, prasterone, thalidomide and retinoids. NSAIDs were not included as they are commonly used to treat non-lupus indications (especially for pain relief) and some could be obtained as non-prescription medication. For this analysis, change in therapy was categorized into ‘increase in therapy’ and ‘no increase in therapy’.

Yee C.S., Cresswell L., Farewell V., Rahman A., Teh L.S., Griffiths B., Bruce I.N., Ahmad Y., Prabu A., Akil M., McHugh N., D’Cruz D., Khamashta M.A., Isenberg D.A, & Gordon C. (2010). Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford, England), 49(9), 1665-1669.

Publication 2010

Anti-Inflammatory Agents, Non-Steroidal Antimalarials Coagulation, Blood Drugs, Non-Prescription Glucocorticoids Immunosuppressive Agents Intravenous Immunoglobulins Lupus Vulgaris Pain Pharmaceutical Preparations Plasmapheresis Prasterone Retinoids Thalidomide Therapeutics Therapies, Biological

Coagulation Abnormalities in Severe COVID-19

Consecutive patients with severe COVID‐19 admitted to Tongji Hospital of Huazhong University of Science and Technology in Wuhan from January 1 to February 13, 2020, were retrospectively enrolled. Exclusion criteria were a bleeding diathesis, hospital stay < 7 days, lack of information about coagulation parameters and medications, and age < 18 years. A retrospective review of the characteristics of these patients was performed through the electronic medical record system of our hospital, the medications and outcomes (28‐day mortality) were monitored up to March 13, 2020. This study was approved by the Ethics Committee of Tongji Hospital (Wuhan, China).
The diagnosis of COVID‐19 was according to World Health Organization interim guidance⁸ and confirmed by RNA detection of the SARS‐CoV‐2 in a clinical laboratory of the Tongji hospital. Severe COVID‐19 was defined as meeting any one of following items, according to the Diagnosis and Treatment Plan of COVID‐19 suggested by National Health Commission of China⁹ : Respiratory rate ≥30 breaths/min; arterial oxygen saturation ≤93% at rest; PaO₂/FiO₂ ≤ 300 mm Hg.
The SIC score system including prothrombin time (PT), platelet count, and sequential organ failure assessment (SOFA) was described in Table 1,⁶ (link) in which the SOFA score contained four items and was originally developed by an international group of experts to describe the time course of muitiple organ dysfunctions using a limited number of routinely measured variables.¹⁰ (link) Meanwhile, in our previous study,³ (link) higher D‐dimer and PT on admission were associated with poor prognosis in patients with COVID‐19. Hence these three parameters were included in this study and the results were recorded at the time the patient meeting the definition of severe COVID‐19. Anticoagulant treatment group was defined as receiving unfractionated heparin or low molecular weight heparin (LMWH) for 7 days or longer,¹¹ (link) which was the most commonly used anticoagulant therapy for COVID‐19 in our hospital.Table 1

ISTH SIC scoring system

Table 1

Item	Score	Range
Platelet count (×10⁹/L)	1	100‐150
Platelet count (×10⁹/L)	2	<100
PT‐INR	1	1.2‐1.4
PT‐INR	2	>1.4
SOFA score	1	1
SOFA score	2	≥2
Total score for SIC	≥4

Abbreviations: INR, International Normalized Ratio; SOFA, sequential organ failure assessment.

The coagulation tests, including PT and D‐dimer, were detected using a STA‐R MAX coagulation analyzer and original reagents (Diagnostica Stago). The platelet counts were analyzed by a Sysmex XE‐2100 hematology analyzer (Sysmex).
Normally and abnormally distributed quantitative variables were compared using the Student's t‐test and the Mann‐Whitney U test, respectively. Categorical variables were compared using the chi‐squared test. The results were given as the mean ± standard deviation, median (interquartile range), or number (percentage), wherever appropriate. Categorical and consecutive variables were evaluated by logistic regression analysis for their ability to predict 28‐day mortality. A P value of < .05 was considered statistically significant. Data were analyzed using SPSS 21.0 for Windows (SPSS Inc).

Tang N., Bai H., Chen X., Gong J., Li D, & Sun Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis, 18(5), 1094-1099.

Publication 2020

Anticoagulants Arteries Blood Coagulation Disorders Coagulation, Blood COVID 19 Diagnosis Ethics Committees, Clinical fibrin fragment D Heparin Heparin, Low-Molecular-Weight International Normalized Ratio Oxygen Saturation Patients Pharmaceutical Preparations Platelet Counts, Blood Prognosis Respiratory Rate SARS-CoV-2 Tests, Blood Coagulation Therapeutics Times, Prothrombin

Trauma Injury Severity Scoring Protocols

All injuries are coded according to the Abbreviated Injury Scale (AIS), version 2008. The AIS codebook contains about 2000 different injuries, each one with an individual severity level ranging from 1 (minor) to 6 (actual untreatable). The TR-DGU uses a reduced version with only 450 codes for documentation where similar codes with the same severity level were merged.
The ISS is calculated from the three worst affected body regions as the sum of squares of the respective AIS severity levels [2 (link)]. The New ISS, or NISS, is calculated in a similar way but here the three worst injuries are selected regardless of their location [7 (link)]. The TRISS is a combination of anatomical injury severity (ISS), the physiological response (Revised Trauma Score with consciousness, blood pressure, and respiratory rate), and age. The TRISS has different formulas for blunt and penetrating trauma mechanism. This score has repeatedly been used and adapted to local trauma registries but we used the original coefficients of Champion et al. in this analysis for reasons of comparability [3 (link)].
The RISC score has been developed with about 1,200 cases from the TR-DGU documented in the years 1993 to 2000. Besides the NISS the following categorical variables were used in the RISC: age, head injury, Glasgow Coma Scale (GCS), coagulation (partial thromboplastin time), base deficit, CPR, number of indirect signs of bleeding (low haemoglobin; hypotension, massive transfusion). For most variables, an algorithm for replacing missing values had been established (for details, see [4 (link)]).

Lefering R., Huber-Wagner S., Nienaber U., Maegele M, & Bouillon B. (2014). Update of the trauma risk adjustment model of the TraumaRegister DGU™: the Revised Injury Severity Classification, version II. Critical Care, 18(5), 476.

Full text: Click here

Publication 2014

Activated Partial Thromboplastin Time Blood Pressure Blood Transfusion Body Regions Coagulation, Blood Consciousness Craniocerebral Trauma Diet, Formula Hemoglobin Injuries physiology Respiratory Rate RNA-Induced Silencing Complex SLC5A5 protein, human Wounds, Penetrating Wounds and Injuries

Immunological Profiling of Healthy Volunteers

The cohort consists of 1,000 healthy volunteers (500 men and 500 women) aged 20–69 y old equally distributed across five decades of life who were selected based on stringent inclusion and exclusion criteria (55 (link)). The study was approved by the Comité de Protection des Personnes—Ouest 6 and the Agence Nationale de Sécurité du Médicament and is sponsored by the Institut Pasteur (ID-RCB no. 2012-A00238-35). The study protocol was designed and conducted in accordance with the Declaration of Helsinki and good clinical practice as outlined in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidelines for Good Clinical Practice (https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf), and all subjects gave informed consent. Stimulations were performed on 1 mL whole blood for 22 h using TruCulture tubes (61 (link)), and flow cytometry analyses were performed with an eight-color cytometry panel (62 (link)). Gene expression was performed using the Human Immunology v2 Gene Expression CodeSet, which contains 594 gene probes that encompass major immune pathways and functions, such as the TLR, Jak-STAT, and MAPK signaling pathways, cytokine–cytokine receptor interactions, apoptosis, and the complement and coagulation cascades. For each gene in each stimulated condition, a paired t test was used to compare expression levels in stimulated and nonstimulated states, controlling for FDR. Seven multiple regression models were built to estimate the effects of age and sex on gene expression. Structural equation modeling (44 ) was used to investigate the ways in which the different cell populations mediate the effects of age and sex on gene expression. DNA genotyping was performed using the HumanOmniExpress-24 BeadChip and the HumanExome-12 BeadChip (Illumina). After imputation using the 1,000 Genomes Project imputation reference panel (45 (link)), a final dataset of 5,265,361 SNPs was obtained. eQTLs mapping was performed with a linear mixed model implemented in GenABEL (63 (link)). Interaction effects between variables (genetics, sex, and age) on gene expression were estimated using ProbABEL v.0.4.5 (64 (link)).
Detailed information about the experimental methods and statistical analyses may be found in SI Materials and Methods.

Piasecka B., Duffy D., Urrutia A., Quach H., Patin E., Posseme C., Bergstedt J., Charbit B., Rouilly V., MacPherson C.R., Hasan M., Albaud B., Gentien D., Fellay J., Albert M.L, & Quintana-Murci L. (2017). Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. Proceedings of the National Academy of Sciences of the United States of America, 115(3), E488-E497.

Publication 2017

Apoptosis BLOOD Cells Coagulation, Blood Conferences Flow Cytometry Gene Expression Genes Genome Healthy Volunteers Hereditary Diseases Homo sapiens MAP Kinase Cascade Pharmaceutical Preparations Population Group Receptors, Cytokine Single Nucleotide Polymorphism Woman

Porcine Blood Clot Formation for Sonothrombolysis

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013

Alteplase Biological Factors BLOOD citrate phosphate dextrose Citrates Citric Acid Clotrimazole Coagulation, Blood Fibrinolytic Agents Glucose Homo sapiens Microbubbles Pigs Retractions, Clot Serum Susceptibility, Disease Therapies, Investigational Thrombus Tissue Donors Ultrasonography Veins

Most recents protocols related to «Coagulation, Blood»

Cervical Radicular Pain Management Protocol

The following patients were eligible for analysis: (1) CR, the diagnostic criteria: Clinical symptoms, physical examination, and confirmation of the unilateral disc herniation via cervical CT or magnetic resonance imaging (MRI); (2) Patients aged >18 years; (3) Lower cervical radicular pain lasting ≤3 months; (4) Numerical rating scale, NRS≥ 4.
The following patients were excluded from analysis: (1) Severe heart disease; (2) Severe spinal deformity; (3) Hypersensitivity to local anesthetics or hormones; (4) Coagulation dysfunction; (5) Systemic infection or skin infection at the puncture site; (6) Patients with abnormal mental behavior, severe anxiety, or depression; (7) Lactating and pregnant women; (8) History of cervical surgery; (9) Cervical spondylotic myelopathy; (10) Moderate and severe foraminal stenosis.

Ma L., Wang Y., Yao M., Huang B., Deng J, & Wen H. (2023). Evaluating the Extent of Ultrasound-Guided Cervical Selective Nerve Root Block in the Lower Cervical Spine: Evidence Based on Computed Tomography Images. Journal of Pain Research, 16, 669-676.

Publication 2023

Anxiety Cellulitis Coagulation, Blood Congenital Abnormality Diagnosis Heart Diseases Hormones Hypersensitivity Intervertebral Disk Displacement Local Anesthetics Mentally Ill Persons Neck Neck Pain Operative Surgical Procedures Patients Physical Examination Pregnant Women Punctures Sepsis Spinal Cord Diseases Spondylosis, Cervical Stenosis Tooth Root

Exclusion Criteria for Arterial Sampling

Those who did not give consent

Existence of contraindications for arterial blood sampling, including impalpable or negative Allen’s test in the upper extremities, infection or fistula at the desired site of puncture, or having severe coagulation disorders

Interval of more than 10 min between arterial and venous sampling and inappropriate sample transfer to the laboratory

Postcardiac arrest patients

Prasad H., Vempalli N., Agrawal N., Ajun U.N., Salam A., Subhra Datta S., Singhal A., Ranjan N., Shabeeba Sherin P.P, & Sundareshan G. (2023). Correlation and agreement between arterial and venous blood gas analysis in patients with hypotension—an emergency department-based cross-sectional study. International Journal of Emergency Medicine, 16, 18.

Full text: Click here

Publication 2023

Arteries Coagulation, Blood Fistula Infection Patient Transfer Punctures Upper Extremity Veins

Retrospective Study of Clinical Features and Treatment Options in Patients

The data collected in this retrospective study were obtained through the hospital's electronic medical record system and included baseline information (sex, age, and past medical history), clinic symptoms (main onset phenotype and state of consciousness), laboratory examinations (blood cell count, total protein, Alb, globulin, coagulation function index, CRP, and FARP), electroencephalogram (EEG), magnetic resonance imaging (MRI), and treatment options. Fasting venous blood was collected from the patients early in the morning after admission. All blood samples acquired for routine blood tests and biomarker identification were analyzed in the biochemistry laboratory of the First Affiliated Hospital of Zhengzhou University. All tests were performed according to the manufacturer's instructions and relevant guidelines, and the inspectors were blinded to all clinical information.

Du J., Shao Y., Song Y., Wang K., Yang X., Li Y., Yao Y., Gong Z, & Jia Y. (2023). Fibrinogen-to-albumin ratio percentage: An independent predictor of disease severity and prognosis in anti-N-methyl-D-aspartate receptor encephalitis. Frontiers in Neurology, 14, 1083752.

Full text: Click here

Publication 2023

Biological Markers BLOOD Blood Cell Count Coagulation, Blood Consciousness Electroencephalography Globulins Hematologic Tests Patients Phenotype Physical Examination Proteins Veins

Safety Evaluation of Experimental Drug

The safety evaluation included assessment of adverse events (AEs), clinical laboratory parameters, vital signs, and ECGs. Blood and urine samples for clinical laboratory parameters (hematology, clinical chemistry, coagulation, and urinalysis) were collected in the fasting state, at screening, prior to study drug administration on days 0, 12, 13, 14, and 15, prior to breakfast on day 16, and at follow-up. Vital signs and ECGs were recorded after 15 min of supine rest at screening, prior to and 5.5 h after study drug administration on days 0, 12 (ECG recorded pre-dose only), 13, 14, and 15, prior to breakfast on day 16, and at follow-up. The hemodynamic profile was also a measure of safety.

Boettcher M., Nowotny B., Krausche R, & Becker C. (2023). Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. Clinical Pharmacokinetics, 62(2), 321-333.

Publication 2023

BLOOD Clinical Laboratory Services Coagulation, Blood Electrocardiogram Hemodynamics Safety Signs, Vital Urinalysis Urine

Anticoagulant Activity of UcB5 Protease

The next experiments were approved by an appropriate institution. In addition to this, all methods were performed following the relevant guidelines and regulations including ARRIVE guidelines. The in vitro anticoagulant activity was examined as the increase in the coagulation period of human blood serum in the existence of 15 µg of UcB5 protease/ml^{15 (link)}. Exactly, 100 µl of blood serum was vortexed with equivalent volumes of each thromboplastin and kaolin. After 2 min incubation at 37 °C in a water bath, exactly 100 µl of 0.3% (w/v) CaCl₂ and 100 µl of the enzyme were added. The clotting time in the presence of the enzyme was then determined in comparison with blanks containing an equivalent amount of physiological saline instead of the purified enzyme.

Kotb E., El-Nogoumy B.A., Alqahtani H.A., Ahmed A.A., Al-shwyeh H.A., Algarudi S.M, & Almahasheer H. (2023). A putative cytotoxic serine protease from Salmonella typhimurium UcB5 recovered from undercooked burger. Scientific Reports, 13, 3926.

Full text: Click here

Publication 2023

Anticoagulants Bath BLOOD clotting enzyme Coagulation, Blood Enzymes Homo sapiens Kaolin Peptide Hydrolases physiology Saline Solution Serum Thromboplastin

Top products related to «Coagulation, Blood»

Cs 5100 by Sysmex

Sourced in Japan, China, United States

The CS-5100 is a fully automated coagulation analyzer designed for high-volume clinical laboratories. It performs a range of coagulation tests, including prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen concentration determination. The system is capable of processing a large number of samples with high efficiency and accuracy.

Vacutainer by BD

Sourced in United States, United Kingdom, Brazil, Germany, Canada, France, Spain, Italy, Switzerland, Australia, Sweden, Belgium, New Zealand, Denmark, Mexico, Jersey, South Sudan, Austria, Japan

The BD Vacutainer is a blood collection system used to collect, process, and preserve blood samples. It consists of a sterile evacuated glass or plastic tube with a closure that maintains the vacuum. The Vacutainer provides a standardized method for drawing blood samples for laboratory analysis.

Vio300d by Erbe

Sourced in Germany, United States, Japan

The VIO300D is a high-performance electrosurgical generator. It is designed for use in a variety of surgical procedures, providing precise control and consistent cutting and coagulation performance.

Ca 1500 by Sysmex

Sourced in Japan, Germany, United States

The CA-1500 is an automated coagulation analyzer manufactured by Sysmex. It is designed for the measurement and analysis of coagulation parameters in clinical laboratory settings. The CA-1500 utilizes optical detection methods to perform a variety of coagulation tests, providing reliable and accurate results to support patient care.

Au5800 by Beckman Coulter

Sourced in United States, Japan, Germany, United Kingdom, China, Italy, Canada

The AU5800 is a chemistry analyzer designed for high-throughput clinical laboratory testing. It features advanced optics and automation to provide reliable and efficient sample processing. The core function of the AU5800 is to perform a variety of clinical chemistry tests, including immunoassays, on patient samples.

Ca 7000 by Sysmex

Sourced in Japan, Germany

The CA-7000 is an automated coagulation analyzer developed by Sysmex. It is designed to perform a variety of coagulation tests, including prothrombin time (PT), activated partial thromboplastin time (APTT), and other coagulation-related assays. The CA-7000 features high throughput, precise results, and streamlined workflow to support laboratory testing needs.

Gif q260j by Olympus

Sourced in Japan, United Kingdom, Germany

The GIF-Q260J is a laboratory equipment product from Olympus. It is designed to perform a core function, but the specific details of its intended use are not available in this concise, unbiased, and factual description.

Vacuette by Greiner

Sourced in Austria, Germany, United States, United Kingdom, Belgium, Switzerland, Italy, France, Spain, Brazil

The Vacuette is a laboratory equipment designed to collect and store blood samples. It provides a closed vacuum system to draw blood samples efficiently and safely.

Xe 2100 by Sysmex

Sourced in Japan, Germany, United Kingdom, United States, Brazil

The XE-2100 is a hematology analyzer designed for automated blood cell analysis. It provides comprehensive analysis of various blood cell types, including red blood cells, white blood cells, and platelets. The XE-2100 is capable of performing a wide range of hematological tests and measurements to support clinical decision-making.

What are the different types or variations of blood coagulation?

Blood coagulation can occur through several different pathways, including the intrinsic, extrinsic, and common pathways. The intrinsic pathway is activated by contact with negatively charged surfaces, while the extrinsic pathway is triggered by the release of tissue factor. These pathways converge on the common pathway, which leads to the formation of fibrin and a stable blood clot. Understanding the nuances of these pathways is important for developing targeted therapies and monitoring coagulation disorders.

How can PubCompare.ai help with optimizing blood coagulation research protocols?

PubCompare.ai allows you to streamline your blood coagulation research by helping you more efficiently screen the protocol literature. The platform's AI-driven analysis can pinpoint critical insights, allowing you to identify the most effective protocols related to blood coagulation for your specific research goals. By highlighting key differences in protocol effectiveness, PubCompare.ai enables you to choose the best option for reproducibility and accuracy, taking your coagulation studies to new heights.

What are some common challenges in working with blood coagulation protocols?

One of the main challenges in working with blood coagulation protocols is ensuring reproducibility and consistency across experiments. Factors like sample preparation, reagent quality, and environmental conditions can all impact the coagulation process and lead to variability in results. Additionally, the complex interplay between different coagulation pathways and factors can make it difficult to isolate and study specific mechanisms. PubCompare.ai can help address these challenges by providing guidance on the most robust and well-vetted protocols, as well as surfaceing critical insights to help you navigate the nuances of coagulation research.

How can blood coagulation protocols be applied in different research and clinical settings?

Blood coagulation protocols have a wide range of applications, from basic research into the underlying mechanisms of clot formation to clinical diagnostics and therapeutic development. In research settings, coagulation protocols are used to study the effects of various stimuli, medications, or genetic factors on the clotting process. In the clinic, coagulation assays are used to diagnose and monitor disorders like hemophilia, thrombophilia, and disseminated intravascular coagulation. Additionally, coagulation research has implications for the development of anticoagulant drugs, surgical hemostasis techniques, and advanced wound healing therapies. PubCompar.ai can help identify the most relevant and effective protocols for your specific application, whether it's in a research lab or a clinical setting.

What are some best practices for using PubCompare.ai to optimize blood coagulation research?

To get the most out of PubCompare.ai for your blood coagulation research, we recommend starting by clearly defining your research goals and the specific questions you're trying to answer. This will help the platform's AI-driven analysis surface the most relevant and valuable protocol comparisons. Additionally, be sure to leverage PubCompare.ai's advanced filtering and sorting tools to quickly identify the protocols that best match your needs in terms of factors like sample type, experimental design, and measured outcomes. Finally, don't hesitate to reach out to the PubCompare.ai team if you need any guidance or assistance in navigating the platform - their experitse can be invaluable for optimizing your coagulation studies.

More about "Coagulation, Blood"

Hemostasis, Thrombosis, Platelet Activation, Coagulation Cascade, Fibrin Formation, Clotting Factors, Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Thromboelastography (TEG), Rotational Thromboelastometry (ROTEM), Hematology Analyzers (e.g., XE-2100, BD Vacutainer, Vacuette), Coagulation Analyzers (e.g., CA-1500, AU5800, CA-7000, GIF-Q260J), Coagulation Assays, Anticoagulants, Thromboprophylaxis, Bleeding Disorders, Thrombotic Disorders, Personalized Hemostasis Management, Precision Medicine in Coagulation.
The process of blood clot formation, known as coagulation or hemostasis, is a complex and vital physiological mechanism that helps stop bleeding and promote healing.
It involves the intricate interactions between blood vessels, blood platelets, and numerous coagulation factors.
Researchers utilize advanced analytical tools like hematology and coagulation analyzers (e.g., XE-2100, BD Vacutainer, Vacuette, CA-1500, AU5800, CA-7000, GIF-Q260J) to study and optimize coagulation and blood research protocols, enabling them to uncover the most efficient and effective published methods to advance their studies in this critical area of biomedical research.